ENTRADA THERAPEUTICS, INC. (TRDA) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $4.00K; Additional Paid in CapitalUSD $588.91M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $66.00K; Retained Earnings (Accumulated Deficit)USD $-355.57M.
- 2026-03-31: Common Stock, Value, IssuedUSD $4.00K; Additional Paid in CapitalUSD $583.41M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $246.00K; Retained Earnings (Accumulated Deficit)USD $-312.81M.
- 2025-12-31: Common Stock, Value, IssuedUSD $4.00K; Additional Paid in CapitalUSD $578.57M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $652.00K; Retained Earnings (Accumulated Deficit)USD $-273.09M.
- 2025-09-30: Common Stock, Value, IssuedUSD $4.00K; Additional Paid in CapitalUSD $574.02M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $621.00K; Retained Earnings (Accumulated Deficit)USD $-233.93M.
ENTRADA THERAPEUTICS, INC. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $4.00K | $588.91M | $66.00K | $-355.57M | $233.41M | 3 month · $5.15M | (m) |
| 2026-03-31 | $4.00K | $583.41M | $246.00K | $-312.81M | $270.85M | 3 month · $4.74M | (m) |
| 2025-12-31 | $4.00K | $578.57M | $652.00K | $-273.09M | $306.13M | 12 month · $19.61M | (m) |
| 2025-09-30 | $4.00K | $574.02M | $621.00K | $-233.93M | $340.72M | 3 month · $5.12M | (m) |
| 2025-06-30 | $4.00K | $568.90M | $400.00K | $-189.80M | $379.50M | 3 month · $5.05M | (m) |
| 2025-03-31 | $4.00K | $563.51M | $437.00K | $-146.69M | $417.26M | 3 month · $5.09M | (m) |
| 2024-12-31 | $4.00K | $558.06M | $-43.00K | $-129.34M | $428.68M | 12 month · $17.91M | (m) |
| 2024-09-30 | $4.00K | $551.95M | $972.00K | $-130.47M | $422.45M | 3 month · $4.86M | (m) |
| 2024-06-30 | $4.00K | $546.69M | $-329.00K | $-116.44M | $429.93M | 3 month · $4.62M | (m) |
| 2024-03-31 | $3.00K | $441.08M | $-246.00K | $-171.47M | $269.37M | 3 month · $3.73M | (m) |
| 2023-12-31 | $3.00K | $437.13M | $195.00K | $-194.97M | $242.36M | 12 month · $13.11M | (m) |
| 2023-09-30 | $3.00K | $432.58M | $-496.00K | $-185.43M | $246.66M | 3 month · $3.40M | (m) |
| 2023-06-30 | $3.00K | $428.80M | $-1.00M | $-220.89M | $206.91M | 3 month · $3.12M | (m) |
| 2023-03-31 | $3.00K | $425.21M | $-642.00K | $-194.96M | $229.61M | 3 month · $2.75M | (m) |
| 2022-12-31 | $3.00K | $402.89M | $-2.06M | $-188.28M | $212.55M | 12 month · $9.89M | (m) |
| 2022-09-30 | $3.00K | $399.62M | $-2.75M | $-163.66M | $233.22M | 3 month · $2.71M | (m) |
| 2022-06-30 | $3.00K | $396.82M | $-2.27M | $-138.52M | $256.04M | 3 month · $2.51M | (m) |
| 2022-03-31 | $3.00K | $394.26M | $-1.53M | $-115.34M | $277.39M | 3 month · $1.79M | (m) |
| 2021-12-31 | $3.00K | $392.38M | $0.00 | $-93.67M | $298.72M | 12 month · $2.53M | 12 month · $18.03M |
| 2021-09-30 | (m) | $2.63M | (m) | $-75.22M | $-72.59M | 3 month · $577.00K | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | $-59.01M | 3 month · $326.00K | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | $-49.67M | 3 month · $164.00K | (m) |
| 2020-12-31 | (m) | $1.02M | (m) | $-42.51M | $-41.49M | 12 month · $325.00K | 12 month · $420.00K |
| 2020-09-30 | (m) | (m) | (m) | (m) | $-33.05M | 3 month · $75.00K | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | $-26.14M | 3 month · $74.00K | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | $-20.12M | 3 month · $78.00K | (m) |
| 2019-12-31 | (m) | (m) | (m) | (m) | $-15.52M | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |